Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the Prostate

Prostate Cancer Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02822963
• Other study ID #: A-ER-105-045
• Status: Withdrawn
• Start date: March 2016
• Est. completion date: August 2016

Study information

• Verified date: June 2016
• Source: National Cheng-Kung University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Benign prostatic hyperplasia(BPH) is a common disease in urology among old men. If BPH symptom cannot be controlled by drugs, then transurethral resection of the prostate (TURP), is recommended. Although the procedure is quit safe, these old men often take anticoagulants and antiplatelets to control cardiovascular diseases, which arose some concerns for their bleeding risk. The management of anticoagulation in patients undergoing surgical procedures is challenging because interrupting anticoagulation increases the risk of thrombotic events. At the same time, surgery and invasive procedures have associated bleeding risks that are increased by the anticoagulant administration. Now, the recommendation about anticoagulants and antiplatelets discontinuation had no concrete evidence, especially in TURP. Furthermore, there is no relative studies done in Taiwan population, which calls for further investigation.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Admitted to National Cheng Kung University Hospital Urology during the study

• Older than 20 years old

• Agree to participate this study

• Receiving transurethral resection of the prostate for benign prostatic hyperplasia or prostate cancer

Exclusion Criteria:

• Poor expression ability and without close care givers to answer questions

Related Conditions & MeSH terms

• Benign Prostatic Hyperplasia
• Hyperplasia
• Prostate Cancer
• Prostatic Hyperplasia

Locations

Country	Name	City	State
Taiwan	National Cheng Kung University Hospital	Tainan

Sponsors (1)

Lead Sponsor	Collaborator
National Cheng-Kung University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Perioperative blood transfusion		in 1 week after surgery
Primary	Bladder clots		in 10 days after surgery
Primary	Hematuria		in 10 days after surgery
Primary	Urine tract infection		in 10 days after surgery
Primary	Duration of catheter		in 10 days after surgery
Primary	Duration of hospitalization		in 1 week after surgery
Primary	Cardiovascular event		In 28 days after surgery
Primary	Major bleeding		In 28 days after surgery